靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

doi:10.19438/j.cjoms.2023.03.003

中国口腔颌面外科杂志 ›› 2023, Vol. 21 ›› Issue (3): 225-230.doi: 10.19438/j.cjoms.2023.03.003

靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

汪子恒, 周韧, 严佳, 张磊, 杨雅琼^*, 姜虹^*

上海交通大学医学院附属第九人民医院麻醉科,上海 200011

收稿日期:2023-02-05 修回日期:2023-03-01 出版日期:2023-05-20 发布日期:2023-08-16
通讯作者: 姜虹,E-mail: dr_jianghong@163.com;杨雅琼,E-mail: yangyaqiong228@163.com。^*共同通信作者
作者简介:汪子恒（1997-）,男,在读硕士研究生,E-mail:wzhxzmu@163.com
基金资助:
国家自然科学基金（81801094）

Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain

WANG Zi-heng, ZHOU Ren, YAN Jia, ZHANG Lei, YANG Ya-qiong, JIANG Hong

Department of Anesthesiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received:2023-02-05 Revised:2023-03-01 Online:2023-05-20 Published:2023-08-16

摘要/Abstract

摘要： 目的：比较靶向表皮生长因子受体（epidermal growth factor receptor,EGFR）治疗联合化疗与单纯化疗对口腔癌痛的影响。方法：选择患有慢性癌痛的口腔癌患者90例,根据接受治疗的方式分为单纯化疗组（G0组）和靶向EGFR治疗联合化疗组（G1组）。在患者入院（T0）、治疗后第1天（T1）、第7天（T2）和第3个月末（T3）,使用视觉模拟评分（VAS）和数字疼痛评分表（NRS）评估疼痛强度。在T0和T3,使用自评利兹神经病理性疼痛症状与体征评价量表（S-LANSS）评价患者神经病理性疼痛,记录辅助镇痛药物的使用和睡眠时长;在T3时记录治疗副作用和满意度。采用SPSS 26.0软件包对数据进行统计学分析。结果：G0组和G1组分别纳入31例和59例患者。受试者平均年龄60.64岁,70%为男性。2组患者T0时的VAS和NRS无显著差异,而G1组在T1、T2和T3时的VAS和NRS较G0组显著降低（P<0.05）。G1组较G0组在T3时使用的镇痛药物显著减少（P<0.05）,睡眠时间显著延长（P<0.05）,满意度更高（P<0.05）。结论：靶向EGFR治疗联合化疗相比单纯化疗对口腔癌痛的缓解作用更明显,可减少辅助镇痛药物的使用。

关键词: 口腔癌, 表皮生长因子受体, 化疗, 癌痛

Abstract: PURPOSE: To compare the effect of epidermal growth factor receptor-targeted (EGFR-targeted) therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain. METHODS: Ninety oral cancer patients with chronic cancer pain were divided into chemotherapy alone group (group G0) and EGFR-targeted therapy combined with chemotherapy group (group G1) according to the type of treatment they received. Pain intensity was assessed at baseline (T0), day 1 (T1), day 7 (T2) and at the end of month 3 (T3) using visual analogue scale (VAS) and numerical rating scale for pain(NRS). The patients were assessed for neuropathic pain using self-administrative Leeds neuropathic pain signs and symptoms scale (S-LANSS), and adjunctive analgesic use, sleep duration were recorded at T0 and T3. Treatment side effects and satisfaction were recorded at T3. SPSS 26.0 software package was used to analyze the data. RESULTS: Of the 90 patients, 31 cases were included in G0 group and 59 cases were included in G1 group. The average age of patients was 60.64 years and 70% were male. There was no significant difference in VAS and NRS at T0 between G0 group and G1 group(P>0.05). VAS and NRS at T1, T2 and T3 were significantly lower in G1 group compared to G0 group(P<0.05). Patients in G1 group used significantly less analgesic medication (P<0.05), slept longer(P<0.05) and were more satisfied (P<0.05) than those in G0 group at T3. CONCLUSIONS: EGFR-targeted therapy in combination with chemotherapy are more effective than chemotherapy alone in the alleviation of oral cancer pain and reduce the use of adjuvant analgesics.

Key words: Oral cancer, EGFR, Chemotherapy, Cancer pain

中图分类号:

R739.8

汪子恒, 周韧, 严佳, 张磊, 杨雅琼, 姜虹. 靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响[J]. 中国口腔颌面外科杂志, 2023, 21(3): 225-230.

WANG Zi-heng, ZHOU Ren, YAN Jia, ZHANG Lei, YANG Ya-qiong, JIANG Hong. Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain[J]. China J Oral Maxillofac Surg, 2023, 21(3): 225-230.

参考文献

[1] Bossi P, Giusti R, Tarsitano A, et al.The point of pain in head and neck cancer[J]. Crit Rev Oncol Hematol, 2019, 138: 51-59.
[2] Epstein J B, Elad S, Eliav E, et al.Orofacial pain in cancer: part Ⅱ-clinical perspectives and management[J]. J Dent Res, 2007, 86(6): 506-518.
[3] Celis-Rodríguez E, Díaz Cortés JC, Cárdenas Bolívar YR, et al.Evidence-based clinical practice guidelines for the management of sedoanalgesia and delirium in critically ill adult patients[J]. Med Intensiva (Engl Ed), 2020, 44(3): 171-184.
[4] van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years[J]. Ann Oncol, 2007, 18(9): 1437-1449.
[5] Ayati A, Emami S, Moghimi S, et al.Thiazole in the targeted anticancer drug discovery[J]. Future Med Chem, 2019, 11(15): 1929-1952.
[6] Sharma SV, Bell DW, Settleman J, et al.Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer, 2007, 7(3): 169-181.
[7] Rosell R, Moran T, Queralt C, et al.Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med, 2009, 361(10): 958-967.
[8] Magee D, Bachtold S, Brown M, et al.Cancer pain: where are we now?[J]. Pain Manag, 2019, 9(1): 63-79.
[9] Kersten C, Cameron MG.Cetuximab alleviates neuropathic pain despite tumour progression[J]. BMJ Case Rep, 2012: bcr122011 5374.
[10] Kersten C, Cameron MG, Laird B, et al.Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain[J]. Br J Anaesth, 2015, 115(5): 761-767.
[11] Chong IC, Hardingham JE, Townsend AR, et al.Rechallenge with anti-EGFR therapy in metastatic colorectal cancer (mCRC): results from South Australia mCRC registry[J]. Target Oncol, 2020, 15(6): 751-757.
[12] Martin LJ, Smith SB, Khoutorsky A, et al.Epiregulin and EGFR interactions are involved in pain processing[J]. J Clin Invest, 2017, 127(9): 3353-3366.
[13] Puig S, Donica CL, Gutstein HB. EGFR signaling causes morphine tolerance and mechanical sensitization in rats[J]. eNeuro, 2020, 7(2): eneuro.0460-18.2020.
[14] Yang Y, Sun Y, Hu R, et al.Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway[J]. PLoS One, 2021, 16(9): e0256870.
[15] Yang Y, Chen Z, Hu R, et al.Activation of the spinal EGFR signaling pathway in a rat model of cancer-induced bone pain with morphine tolerance[J]. Neuropharmacology, 2021, 196: 108703.
[16] 孙丽立,白玉贤. 头颈鳞癌的靶向治疗进展[J]. 中华临床医师杂志(电子版), 2013, 7(22): 10271-10274.
Sun LL, Bai YX.Advances in targeted therapy for head and neck squamous cell carcinoma[J]. Chinese Journal of Clinician (electronic edition), 2013, 7(22): 10271-10274.
[17] 魏东亮,李智,鞠侯雨, 等. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
Wei DL, Li Z, Ju HY, et al.Mechanism of EGFR-targeted drugs for pain relief in oral cancer[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 219-224.
[18] Maughan TS, Adams RA, Smith CG, et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. Lancet, 2011, 377(9783): 2103-2114.
[19] Melosky B, Leighl NB, Rothenstein J, et al.Management of egfr tki-induced dermatologic adverse events[J]. Curr Oncol, 2015, 22(2): 123-132.
[20] Kersten C, Cameron MG, Bailey AG, et al.Relief of neuropathic pain through epidermal growth factor receptor inhibition: a randomized proof-of-concept trial[J]. Pain Med, 2019, 20(12): 2495-2505.

靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李贵忠, 李洁莹, 周凯, 孟宇翔, 王可心, 葛胜优, 宋凯, 冯元勇, 陶月琴, 展晓红, 尚伟. 淋巴结外扩展对口腔鳞癌患者TNM分期及生存预后的影响[J]. 中国口腔颌面外科杂志, 2023, 21(4): 377-383.
[2]	陈伟良. 延长垂直下斜方肌岛状肌皮瓣修复重建大型头颈部缺损[J]. 中国口腔颌面外科杂志, 2023, 21(1): 1-10.
[3]	周瑜, 翁海燕, 司呈云, 段贤捷, 安星妃, 章礼玉. 第8版TNM分期修订版对早期口腔黏膜鳞癌患者预后及危险分层作用的临床研究[J]. 中国口腔颌面外科杂志, 2022, 20(6): 571-576.
[4]	吴梓谦, 殷玉兰, 杨文玉, 张贞, 侯黎莉, 王磊. 口腔癌患者术后舌神经功能障碍与生活质量的关系评价[J]. 中国口腔颌面外科杂志, 2022, 20(5): 449-454.
[5]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[6]	樊文慧, 劳峥, 石慧烽, 毕帆, 涂文勇, 胡海生. 3D打印可分离式口腔支架在口腔癌放疗中的摆位准确性研究[J]. 中国口腔颌面外科杂志, 2022, 20(5): 466-470.
[7]	赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.
[8]	朱博文, 庄海, 毛秋怡, 卜寿山. 4种评分系统判断口腔癌患者术后气管切开需求的准确性评价[J]. 中国口腔颌面外科杂志, 2022, 20(2): 129-134.
[9]	肖育栋, 郭凯欣, 杨乐, 邓威, 曾滨, 张思恩, 劳小媚, 廖贵清, 梁玉洁. 369例口腔癌患者汉语普通话语音数据库的建立与初步评价[J]. 中国口腔颌面外科杂志, 2022, 20(2): 151-157.
[10]	谈亦然, 赵铜超, 王丽珍, 李江, 琚梧桐, 朱东旺, 张志愿, 钟来平. Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(3): 217-221.
[11]	戴振霖, 艾哈迈德·阿德热罕穆, 陈一铭, 汪轶, 季彤. 新辅助化疗治疗头颈部骨肉瘤单中心临床效果回顾[J]. 中国口腔颌面外科杂志, 2021, 19(2): 132-137.
[12]	周凯, 李恒勇, 齐晓杰, 葛胜优, 孔钰, 宋凯, 冯元勇, 侯峰, 史海磊, 蒋艳霞, 尚伟. 口腔癌浸润深度对改进肿瘤TNM分期及预后评价的影响[J]. 中国口腔颌面外科杂志, 2021, 19(2): 138-145.
[13]	姚麟, 郭萌萌, 邓璋, 曾威. 改良负压封闭引流术在游离皮瓣修复术后供区植皮中的应用[J]. 中国口腔颌面外科杂志, 2021, 19(2): 163-166.
[14]	潘梦琪, 李志勇, 赵文权. ASCO指南解读：“口腔和口咽鳞状细胞癌颈部管理”[J]. 中国口腔颌面外科杂志, 2021, 19(2): 177-180.
[15]	张鑫睿, 江旖婷, 张晗之, 张美芳, 张海峰, 孙娟, 任国欣. 28例晚期口腔鳞癌患者新辅助化疗围化疗期营养状况及生活质量评估[J]. 中国口腔颌面外科杂志, 2020, 18(6): 516-520.